(Q39577741)

English

The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models

scientific article published on 11 March 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 September 2017

The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models (English)

1 reference

Europe PubMed Central

13 September 2017

brain metastasis

1 reference

based on heuristic

inferred from title

triple-negative breast cancer

1 reference

based on heuristic

inferred from title

Stephen T C Wong

12

object named as

Stephen T C Wong

1 reference

Europe PubMed Central

13 September 2017

author name string

Hong Zhao

1

1 reference

Europe PubMed Central

13 September 2017

Kemi Cui

2

1 reference

Europe PubMed Central

13 September 2017

Fang Nie

3

1 reference

Europe PubMed Central

13 September 2017

Lulu Wang

4

1 reference

Europe PubMed Central

13 September 2017

Miriam B Brandl

5

1 reference

Europe PubMed Central

13 September 2017

Guangxu Jin

6

1 reference

Europe PubMed Central

13 September 2017

Fuhai Li

7

1 reference

Europe PubMed Central

13 September 2017

Yong Mao

8

1 reference

Europe PubMed Central

13 September 2017

Zhong Xue

9

1 reference

Europe PubMed Central

13 September 2017

Angel Rodriguez

10

1 reference

Europe PubMed Central

13 September 2017

Jenny Chang

11

1 reference

Europe PubMed Central

13 September 2017

language of work or name

0 references

publication date

11 March 2011

1 reference

Europe PubMed Central

13 September 2017

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

13 September 2017

131

1 reference

Europe PubMed Central

13 September 2017

2

1 reference

Europe PubMed Central

13 September 2017

425-436

1 reference

Europe PubMed Central

13 September 2017

https://scigraph.springernature.com/pub.10.1007/s10549-011-1420-7

0 references

Triple-negative breast cancer: therapeutic options

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

Metastatic behavior of breast cancer subtypes

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

Subtypes of breast cancer show preferential site of relapse

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

Classification of genomic changes in breast cancer brain metastasis.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

Adaptation of energy metabolism in breast cancer brain metastases.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

Cost of Migration: Invasion of Malignant Gliomas and Implications for Treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

Rapamycins: mechanism of action and cellular resistance

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

Genes that mediate breast cancer metastasis to the brain

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

WebGestalt: an integrated system for exploring gene sets in various biological contexts

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

A multigenic program mediating breast cancer metastasis to bone

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

Genes that mediate breast cancer metastasis to lung

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

Breast cancer metastasis to the central nervous system

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

Latent bone metastasis in breast cancer tied to Src-dependent survival signals

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell migration

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

Modulation of collagen and MMP-1 gene expression in fibroblasts by the immunosuppressive drug rapamycin. A direct role as an antifibrotic agent?

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

Sirolimus: a ten-year perspective

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1420-7

21 January 2018

Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.28.727

Identifiers

10.1007/S10549-011-1420-7

1 reference

Europe PubMed Central

13 September 2017

1 reference

Europe PubMed Central

13 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39577741&oldid=2127715627"